Craig-Hallum Rates PepGen (PEPG) buy, $11 Price Target

PepGen Inc. received a reaffirmed buy rating from Craig-Hallum with an $11 price target, a 501.09% upside from the current price.

By TradeTexts Research Desk · Published Jun 17, 2026, 2:02 AM EDT · Updated Jun 23, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Craig-Hallum rated PepGen Inc. ($PEPG) "buy" with a $11 price target on June 16, 2026.

Since the rating, $PEPG is up 14.5% after 1 week, up 41.5% after 1 month and up 63.5% to date (from the $1.59 close on Jun 16, 2026).

PEPG PepGen Inc.

$2.60 -63.74% year to date

Daily close · Oct 16, 2026

Key Points

Craig-Hallum analyst Adam Vogel reiterated a buy rating for PepGen Inc. (PEPG) with a price target of $11.
Craig-Hallum's $11 price target implies 501.09% upside from PepGen Inc.'s ($PEPG) current $1.83 share price.
PepGen Inc. trades at $1.53 on NasdaqGS with a market cap of about $110 million and a 52-week range from $1.01 to $7.80.
Insider transactions include CEO James McArthur buying 187,688 shares on March 1, 2026, while Craig-Hallum maintains a strong buy consensus.

Get $PEPG trade alerts by text

We text you when insiders, Congress or big funds trade $PEPG. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated PepGen Inc. alert may contain errors. Disclosures

Craig-Hallum has reiterated its buy rating for PepGen Inc. (NasdaqGS: PEPG) with a price target of $11, according to analyst Adam Vogel on June 16, 2026. PepGen's stock is currently trading at $1.53.

Other Institutional Activity in PepGen Inc.

RA Capital Management, L.P. holds 20,064,545 shares of PepGen, valued at about $35.5 million, with no change in its holdings. Commodore Capital LP increased its stake by 1,075,000 shares, bringing its total to 4,475,000 shares worth approximately $7.9 million. Laurion Capital Management LP grew its holdings by 698,722 shares to a total of 2,750,855 shares, valued at around $4.9 million. Meanwhile, Millennium Management LLC made a significant addition of 1,881,200 shares, totaling 2,079,143 shares valued at roughly $3.7 million.

PepGen Inc. Stock Down 35.8%

Shares of PepGen Inc. (NasdaqGS: PEPG) are trading near $1.53. The company has a market capitalization of approximately $110 million. It is not currently profitable, which means it has no meaningful P/E ratio. The stock's 52-week range spans from $1.01 to $7.80, with a 50-day moving average of $1.59 and a 200-day moving average of $4.05. PepGen maintains a strong current ratio of 14.98 and a quick ratio of 14.76, with a debt-to-equity ratio of 12.36.

12-month forecast

$PEPG price target

PepGen Inc. daily closes and this analyst's $11 target. Not advice.

Insider Buying and Selling at PepGen Inc.

Recent insider transactions at PepGen include CEO James McArthur purchasing 187,688 shares on March 1, 2026. Chief Technical Officer Kasra Kasraian also acquired 135,000 shares on the same day. In contrast, several insiders, including Chief Financial Officer Noel Donnelly and CEO James McArthur, sold shares on March 4, 2026, at an average price of $6.23.

Analysts Set New Price Targets

On June 16, 2026, Craig-Hallum reiterated its buy rating for PepGen with an $11 price target. Previously, on May 13, 2026, Wedbush maintained a buy rating with a $4 target. Oppenheimer initiated coverage with a buy rating and a $15 target on February 25, 2026. The consensus among analysts is a strong buy, with an average target price of $10.14 based on seven opinions.

About PepGen Inc.

PepGen Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company is advancing its lead product candidates, PGN-EDODM1 and FREEDOM2-DM1, through Phase 2 clinical trials for myotonic dystrophy type 1. Founded in 2018, PepGen is led by CEO Dr. James G. McArthur and employs 56 people.

Bottom Line

Craig-Hallum's reiterated buy rating with an $11 target underscores continued confidence in PepGen's potential. Investors closely watch these analyst ratings as they provide insights into market sentiment. It's important to remember that these ratings and targets are based on past data and may not reflect current market conditions.